Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site

Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak's Holmes Chapel site to support the next phase of Chiesi's Carbon Minimal Inhaler (CMI) program. Business Wire

Article content

Highlights

Article content

Article content

Article content

Article content

PARMA, Italy & HOLMES CHAPEL, England — Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.

Article content

Article content

Article content

Building on years of collaboration, the agreement reflects a shared long-term vision: delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients. Both companies are committed to addressing climate change through measurable, science-based action. Chiesi’s ambition to reach Net Zero targets by 2035, and Bespak’s validated decarbonization roadmap, underpin a partnership grounded in shared sustainability principles.

Article content

Maria Paola Chiesi

Article content

,

Article content

Chiesi Group Vice Chair

Article content

, said: “At Chiesi,

Article content

sustainability

Article content

is not an add-on; it is a

Article content

commitment

Article content

that guides our strategic choices. We know that

Article content

inhalers

Article content

are essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients. The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”

Article content

To meet the needs of patients and reduce impact on the environment, Chiesi is working to be the only company to offer a portfolio of extrafine formulation Carbon Minimal Inhalers, including both dry powder inhalers (DPIs) and next generation propellant pMDIs. Chiesi’s CMI program is designed to significantly reduce the carbon footprint of pMDIs by up to 90%, through the transition to a next-generation, low global warming potential (GWP) propellant, while maintaining established treatment options and device familiarity for patients. Reinforcing the partnership with Bespak adds industrial scale and resilience to Chiesi’s journey, supporting a phased and responsible transition.

Article content

The expanded collaboration further strengthens Bespak’s position at the forefront of the global industry’s transition to next-generation, low-GWP propellants, and its Holmes Chapel site as a specialist pMDI manufacturing hub within the global pharmaceutical supply chain. Positioned in the North West of England’s inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide.

Article content

Article content

Giuseppe Accogli

Article content

,

Article content

Chiesi Group CEO

Article content

, added:

Article content

Article content

“This agreement strengthens an already established partnership with Bespak, and is a

Article content

concrete example of how we translate our ambition into action

Article content

. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”

Article content

Chris Hirst

Article content

,

Article content

Bespak CEO

Article content

, said: “Our collaboration with Chiesi has grown over time around a

Article content

shared commitment to patient safety, technical excellence and sustainability

Article content

. By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the

Article content

UK’s role as a center of excellence for sustainable inhalation manufacturing

Article content

. This is a position being recognized by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies.”

Article content

About Chiesi Group

Article content

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

Article content

For more information, visit chiesi.com or the website of your local Chiesi affiliate.

Article content

About Bespak

Article content

Bespak is a specialist inhalation contract development and manufacturing organisation (CDMO) focused on pulmonary and nasal drug delivery. Trusted by the world’s leading pharmaceutical companies, Bespak delivers end-to-end capabilities across product development, clinical supply and commercial manufacturing of inhaled therapies for global supply.